5 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 70 points (0.5%) at 14,846 as of Wednesday, Aug. 28, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,865 issues advancing vs. 1,062 declining with 104 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 1.8%, Valeant Pharmaceuticals International ( VRX), up 1.6%, Alexion Pharmaceuticals ( ALXN), up 1.4% and Eli Lilly and Company ( LLY), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen Idec is up $2.93 (1.4%) to $210.58 on light volume. Thus far, 266,783 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $206.60-$210.89 after having opened the day at $208.27 as compared to the previous trading day's close of $207.65.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $50.5 billion and is part of the health care sector. Shares are up 45.1% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.37 (0.9%) to $42.04 on light volume. Thus far, 2.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $41.37-$42.09 after having opened the day at $41.69 as compared to the previous trading day's close of $41.67.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $69.8 billion and is part of the health care sector. Shares are up 27.9% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Celgene Corporation ( CELG) is up $2.28 (1.7%) to $139.24 on average volume. Thus far, 1.3 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $135.51-$139.41 after having opened the day at $136.79 as compared to the previous trading day's close of $136.96.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $58.1 billion and is part of the health care sector. Shares are up 79.9% year to date as of the close of trading on Tuesday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Gilead ( GILD) is up $1.50 (2.5%) to $60.24 on light volume. Thus far, 3.1 million shares of Gilead exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $58.50-$60.24 after having opened the day at $58.83 as compared to the previous trading day's close of $58.74.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $92.5 billion and is part of the health care sector. Shares are up 64.5% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.32 (1.1%) to $28.31 on light volume. Thus far, 15.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 56.4 million shares. The stock has ranged in price between $27.81-$28.37 after having opened the day at $27.95 as compared to the previous trading day's close of $28.00.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $185.5 billion and is part of the health care sector. Shares are up 11.6% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Italian Bonds Slump as Government Mulls Anti-Euro Finance Minister

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI